Last checked at 24 Apr 2023 16:15
Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 24 April 2023: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 25 February 2021 under the 2014 Executive Incentive Plan ("EIP") Element B and 27 February 2020 under the EIP Element C.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Said Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Chairman and Chief Executive Officer |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 34,827 |
d) | Aggregated information - Volume - Price
- Total |
34,827 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 27,057 |
d) | Aggregated information - Volume - Price
- Total |
27,057 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Mazen Darwazah |
2 | Reason for the notification | |
a) | Position/status | Executive Vice Chairman |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 24,319 |
d) | Aggregated information - Volume - Price
Total |
24,319 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 18,831 |
d) | Aggregated information - Volume - Price
Total |
18,831 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Riad Mishlawi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 20,285 |
d) | Aggregated information - Volume - Price
- Total |
20,285 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 17 April 2023 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 22,437 |
d) | Aggregated information - Volume - Price
- Total |
22,437 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Majda Labadi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Majda Labadi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 11,205 |
d) | Aggregated information - Volume - Price
- Total |
11,205 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 17 April 2023 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 10,690 |
d) | Aggregated information - Volume - Price
- Total |
10,690 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Bassam Kanaan |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 17,307 |
d) | Aggregated information - Volume - Price
- Total |
17,307 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on 17 April 2023 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 17,007 |
d) | Aggregated information - Volume - Price
- Total |
17,007 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Khalid Nabilsi |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 17,390 |
d) | Aggregated information - Volume - Price
- Total |
17,390 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element C. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 17,180 |
d) | Aggregated information - Volume - Price
- Total |
17,180 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Brian Hoffmann
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Brian Hoffmann |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element B. 4,436 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 7,683
Price(s): £18.065 Volume(s): 4,436 |
d) | Aggregated information - Volume - Price
- Total |
12,119 £18.065 £80,136.34 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element C. 4,378 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 7,584
Price(s): £18.065 Volume(s): 4,378 |
d) | Aggregated information - Volume - Price
- Total |
11,962 £18.065 £79,088.57 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Susan Ringdal |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element B. 3,990 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 4,823
Price(s): £18.065 Volume(s): 3,990 |
d) | Aggregated information - Volume - Price
- Total |
8,813 £18.065 £72,079.35 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element C 4,017 Shares were sold to cover tax and the remainder were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 4,857
Price(s): £18.065 Volume(s): 4,017 |
d) | Aggregated information - Volume - Price
- Total |
8,874 £18.065 £72,567.105 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | |
a) | Name | Hussein Arkhagha |
2 | Reason for the notification | |
a) | Position/status | PDMR |
b) | Initial notification /Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Hikma Pharmaceuticals PLC |
b) | LEI | 549300BNS685UXH4JI75 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards on17 April 2023 under the EIP Element B. All Shares were retained. |
c) | Price(s) and volume(s) | Price(s): £nil Volume(s): 7,867 |
d) | Aggregated information - Volume - Price
- Total |
7,867 £0.00 £0.00 |
e) | Date of the transaction | 17 April 2023 |
f) | Place of the transaction | London Stock Exchange (XLON) |
Hussein ArkhaghaChief Counsel and Company Secretary
+44 (0) 20 7399 2760
24 April 2023